Whole cell in vitro screening for gametocytocidal compounds.
Abstract/Summary
The discovery of new chemical starting points with the ability to inhibit Plasmodium falciparum sexual stages, and therefore block the disease transmission, is urgently required. These will form the basis for the development of new therapeutic combinations for the treatment and elimination of malaria and the ultimate goal of global eradication. Recent screening of large chemical libraries against the parasite asexual stages has resulted in the public availability of focused subsets of known antimalarial actives, which represent an excellent starting point for the identification of new gametocytocidal compounds. New stage-specific methodologies aimed at increasing the throughput for assessing compound activity against in vitro cultured gametocytes have recently been published.
This article discusses the challenges of assay-oriented large scale gametocyte culturing and reviews the state of the art in gametocytocidal assay development and outcomes.
Blocking malaria transmission through drugs
Plasmodium falciparum malaria remains a major worldwide public health problem, claiming >1 million lives annually and resulting in almost 200 million clinical cases every year, mainly in developing countries, and predominantly effecting children under the age of five [1] . The clinical manifestations of this parasitic disease are due to the asexual replication of the P. falciparum parasite in the human host blood stream. One complete asexual life cycle takes approximately 48 hours from the initial invasion of an erythrocyte to the subsequent invasion with new progeny. The transmission of the disease is linked to the sexual forms of the parasite, namely the gametocytes, which are present as a minor population in the blood stream of the human host and, although clinically irrelevant, constitute the only malaria parasite forms that can be transmitted to, and survive in, the Anopheles mosquito vector. Gametocytes initiate sexual reproduction in the human blood ingested by the mosquito vector during feeding, which progresses into a multi-stage development process called sporogony, ending in the formation of sporozoites, the stages capable of being transmitted back to the human host during a mosquito bite [2] , and thus the cycle continues (figure 1). Figure 1 . Simplified Plasmodium falciparum life cycle, focusing on gametocytogenesis. Sexually committed schizonts, appearing in the asexual parasite population as a result of multiple sexual differentiation inducing factors, give origin to ring stages (not shown) which in turn obligatorily develop into gametocytes. Scale bar represents 10µm.
During the last decade a renewed commitment to the ambitious goal of global malaria eradication has resulted in unprecedented international support for malaria research, specifically control efforts based on artemisinin-based combination therapy (ACT) [3] and the control of Anopheles mosquito vectors through the use of insecticide impregnated bednets and indoor residual spraying. As a result, important reductions in morbidity and mortality in many malaria endemic countries have been achieved, in some cases even to the point of country-wide elimination of malaria. The most recent examples are Morocco and Turkmenistan in 2010 [101] , with a further 34 countries expected to eliminate malaria within the next 2 decades [102] .
However, to ensure the sustained progress of these efforts towards the goal of malaria eradication, the critical need for transmission blocking agents, either as components of antimalarial therapy or vaccines, has been clearly identified [4] . Reducing the disease transmission by drugs, especially in combination with vector control measures, is not only beneficial in terms of lowering malaria burden (morbidity and mortality) at the community level [5] , but can also decrease the chances of the emergence and spread of drug-resistant parasites [6] . Although many potential transmission blocking targets exist throughout the various transmission stages present in the human and mosquito hosts, gametocytes represent the most convenient stage for transmission blocking drug intervention. This is primarily due to their development in the human host, which therefore makes them more readily accessible than the mosquito stages, and thus druggable [7] . Gametocytes are at present the only P. falciparum transmission stages that have been mass-produced in vitro.
The elimination of P. falciparum gametocytes through drugs, however, is complicated by the peculiarities of this malaria species when compared to other human malaria species, such as P.
vivax, P. ovale, P. malariae. The development of P. falciparum gametocytes is extremely slow, taking at least 7 days from erythrocyte invasion to reaching maturity [8, 9] , through a differentiation process involving 5 morphologically distinct stages [10] (defined as I to V, figure 1), and the sequestration of the immature stages (I-IV) from circulation into the bone marrow and the spleen [11, 12] . Recent evidence suggests that gametocyte sequestration and subsequent release may not rely heavily on ligand-receptor-based cytoadhesion interactions [13] , but rather depend on the ability of early stage gametocytes to reduce the physical deformability of the host erythrocyte, thus preventing passage through the endothelial slits [14] . At maturity (stage V), gametocytes are released from whence they were sequestered, back into the blood stream through mechanisms not yet well understood. Circulating gametocytes can persist at low levels in the peripheral blood for up to three weeks, well after the clearance of malaria symptoms [15] . If gametocytes are not cleared in a patient during a standard antimalarial treatment course, such persistent reservoirs of parasites are available for continued re-infection of mosquitoes and thus can sustain malaria transmission well after clinical symptoms have abated [16] .
The few currently available treatment options for gametocytes are far from satisfactory with respect to their true impact on malaria transmission. Artemisinin derivatives, such as artesunate and artemether, and 8-aminoquinolines, such as primaquine (see table 2 for structures), represent the only antimalarials with late stage gametocytocidal activity currently employed for therapeutic use [17, 18] . ACTs have been shown to significantly reduce gametocyte density and carriage time [15, 19] , but are unable to completely clear circulating mature stage V gametocytes [19] . In a clinical study the addition of a primaquine dose at the end of ACT treatment reduced gametocyte prevalence to 1/64 and gametocyte carriage to 1/16 of the non-primaquine treatment arm, respectively [20] , reaching submicroscopic levels, i.e. detectable only by molecular methods. On the other hand, the emergence of artemisinin-resistant parasites [21] and the well-known toxicity issues of primaquine, namely the hemolysis in G6PD-deficient individuals, a rather common genetic trait in populations living in malaria-endemic geographic areas [22] , highlight the inadequacies of available therapeutics with respect to gametocytocidal activity. This again emphasizes the urgent need for the development of new antimalarial and gametocytocidal compounds, and their essential integration as components of standard antimalarial therapies.
Several additional compounds have been shown to possess gametocytocidal activity in vitro, some of which are under development, including 8-aminoquinolines, trioxaquines, epoxomicin, methylene blue, tipranavir, riboflavin, 9-anilinoacridines [23] and, more recently, spiroindolones [24] , thiostrepton [25] and novel 4-aminoquinoline derivatives [26] (table 1) . Many of these compounds, however, are structurally related to existing drugs, therefore questions remain about unfavorable characteristics (resistance, toxicity) being "inherited" from the parent compounds. The need for new compounds with novel mechanisms of action against both the asexual stages of the parasite and gametocytes of all development stages remain, thus far, largely unmet. 
Approaches and challenges for in vitro gametocyte culture
Soon after the culturing technique of P. falciparum was made available [32] , gametocytes have been observed in vitro [33] . Gametocytes originate as ring forms and develop into small trophozoite-like stages in 24 hours, but it is not until day 2 that they can be readily distinguished from asexual stages by morphology (see figure 1) . The 'decision' to switch to sexual development, as well as the sex determination, however, occur during the 48 hours of the preceding asexual cycle, as demonstrated by the fact that "sexually committed" schizonts give rise to gametocytes only of the same sex [34, 35] . Despite being the subject of extensive research for decades, the factors determining the transformation of parasites into gametocytes in the human host, and consequently in in vitro culture, remain somewhat elusive [36] .
Environmental changes leading to parasite stress have been consistently correlated to enhanced gametocyte production in vitro. Gametocytogenesis induction has been reported using a drop in the hematocrit level of the culture [37] , the addition of hemoglobin-depleted [38] or lysed [39, 40] erythrocytes, the presence of reticulocytes [41] , the exposure to spent media from asexual cultures [42] or from 'old' cultures containing mature gametocytes [43] .
Host factors, such as hormones and immune serum, as well as chemical compounds and modulators, such as cAMP, caffeine, cholera toxin, and ammonium based compounds have also been found to induce gametocytogenesis [36] . Sub-lethal concentrations of antimalarial drugs, such as chloroquine, also stimulate gametocytogenesis in vitro [44] . In spite of our much deeper understanding of the gametocytogenesis mechanism, as well as the accumulated knowledge on gametocyte biology, genetics and proteomics (reviewed by [12, 36, 45] ), gametocytogenesis induction remains an elusive phenomenon, and the parasite's 'decision' to take the gametocytogenesis pathway is believed to rely on more than a single stimulatory factor. Instead, it is likely that this depends on a complex interplay of multiple environmental factors, some of which are difficult to strictly control in the practical laboratory setting. As a result, the large scale culture of gametocytes for any purpose, and especially for the development of specific HTS assay development, is a challenging task. Not surprisingly, experimental in vitro inductions are often unpredictable in terms of gametocyte yields and viability. The development of a sensitive and reproducible HTS assay depends on the quality of the biological material and on the reproducibility of the methods for its production. Since the sexual switch occurs in the asexual cycle preceding the gametocyte, a strict control of the culturing conditions at which the asexual parasites are grown should already be applied during the 48h preceding the appearance of gametocytes. The routine production of large quantities of gametocytes for compound screening purposes is further complicated by strain-inherent differences in gametocyte production [40] and by the reduced gametocyte conversion after extended periods of in vitro culturing [36] , and which makes it necessary to stock large batches of cryopreserved, high gametocyte producing parasites to be used to regularly reinitiate the culturing. Most of the methods employ synchronized asexual cultures, obtained by one or multiple rounds of D-sorbitol treatment. Medium containing 5% D-sorbitol causes the trophozoite and schizont stageinfected erythrocytes to burst, leaving the ring stages unaffected [46] .
The starting culture hematocrit value does not appear to affect the subsequent gametocyte production. Reducing the hematocrit of the culture, however, was used by some authors as a means to induce gametocytogenesis in assay development [47] [48] [49] [50] [51] . Alternatively, nutritional stress, i.e.
keeping the culture in spent medium or by a partial medium change, has been adopted to stimulate sexual conversion [52] [53] [54] . Of the published literature reviewed, none of the assays routinely used specific compounds to induce gametocytogenesis.
After the induction of gametocytogenesis, several methods employed culture medium containing 50 mM N-acetyl-D-glucosamine (NAG) to gradually rid the gametocyte cultures of "contaminant" asexual parasite stages. NAG, rather than directly killing the asexual parasites, prevents the reinvasion of erythrocytes [55] , therefore resulting in a gradual disappearance of asexually replicating parasites. Fortuitously, gametocytes, as far as we can tell, are unaffected by NAG treatment [56] . Another method of gametocyte purification, often used in combination with NAG treatment, especially if younger gametocytes are required, is the use of the magnetic properties of gametocytes. Malaria parasites accumulate hemozoin, a biologically inert heme-based metabolic waste, produced as a result of hemoglobin digestion. The paramagnetic properties of this compound allow the use of magnetic columns to separate hemozoin-containing cells from uninfected erythrocytes [57] . Gametocytes and asexual stages all contain hemozoin to varying degrees, and the young ring stages are not retained on the magnetic columns, due to the low amount of accumulated hemozoin in the cell. This allows the separation of gametocytes from asexual ring forms. This approach, however, is only possible if the original asexual culture is sorbitol-synchronized.
Alternatively, applying density gradients such as Percoll [58] and Nycodenz [59] allows the concentration / purification of gametocytes in asynchronous cultures, but is a less suitable approach for very young (stage I) gametocytes. Finally, flow cytometry can be applied for both synchronized and asynchronous cultures to isolate any sexual stage or even committed schizonts, but requires a suitable gametocyte-specific fluorescent reporter gene to allow for the discrimination between sexual (or sexually-committed) and asexual parasites [48] .
Unfortunately, the gametocyte conversion rate and total yield are not reported in most of the published gametocyte culture and assay development methods, making it difficult to compare the performance of different protocols. The measure of % gametocytemia is a potential performance indicator, however it is not applicable to methods which include a purification step, as the removal of uninfected erythrocytes and asexual stages results in a pure gametocyte culture being obtained, regardless of the efficiency of gametocyte conversion and production.
The long developmental time of P. falciparum gametocytes, and the changing pattern of their susceptibility to antimalarial drugs during this developmental pipeline, makes it crucial to design culturing methods which can provide a high-yielding production of gametocytes with the highest synchronicity possible. The sensitivity profile of gametocytes to antimalarial drugs changes radically during their development. It is believed that early stage gametocytes are sensitive to many schizonticidal drugs, while late stage or mature gametocytes are often less sensitive or unaffected by them, a common example being chloroquine [60] . To obtain a precise assessment of the activity of unknown compounds in early stage gametocyte screening it is therefore important that the culture is devoid of "contaminant" asexual and late stage gametocytes. On the other hand, for the purpose of a late stage gametocyte assay, it could be argued that synchronicity is achieved anyway at maturity, i.e. from day 7-8 of gametocytogenesis onwards, hence screening performed any time after stage V would be directed against a synchronous mature gametocyte population. Stage V gametocytes, however, though morphologically homogeneous, are still variable in terms of their functional maturity (i.e. the ability to infect mosquitoes), which is based on their age. Although stage V gametocytes can be observed in synchronous cultures from day 7-8 of gametocytogenesis onwards, they are not infective to mosquitoes until days 10-12 [9, 52] . There is also evidence that cultured gametocytes may have a reduced longevity than those isolated from infected individuals.
Usually mature and functional gametocytes are found in the blood of patients for prolonged periods after asexual parasitemia has been cleared, with average circulation times estimated between 2.4 to 6.5 days, and maximum persistence of up to 3 weeks [15, 61] . Cultured gametocytes, however, typically do not survive as long as those identified in vivo, and there is limited evidence from mosquito membrane feeding assays using synchronized, cultured NF54 gametocytes which suggests a rapid decline of infectivity, already occurring in 13 day-old gametocytes [9] . Considering all of these aspects collectively, it appears that a "healthy" late stage gametocyte culture is short lived, and without good synchronicity there could be the risk of a biased, or non-reproducible, response from screening activities with late stage gametocytes.
Gametocytocidal assays
In vitro assays for the screening of chemical compounds on the asexual stages of the parasites have been available since the late 1970s. Traditionally employed assay types include the [
hypoxanthine incorporation [62] method and the measurement of the parasite's lactate dehydrogenase [63] . The urgent need for new antimalarial drugs has recently stimulated the search for new methodologies to allow for higher throughput screening of potential antimalarial compounds. As a consequence, this has resulted in the development of new assays based on the measurement of parasite DNA or RNA content through fluorescent staining using dyes such as SYBR green [64] , DAPI [65] or RNA probes [66] . This approach has been extended beyond traditional total fluorescence intensity approaches to more information rich high content screening [65, 67] . The genetic manipulation of the malaria parasite has also been recently exploited to develop new HTS-ready luminometry [68, 69] assays, based on the measurement of the firefly luciferase reporter gene activity.
Surprisingly, although many of these approaches for drug screening appear readily transferrable to HTS for the gametocyte stages of Plasmodium, methods specifically designed for these sexual stages have only started to be developed in last few years, thus the evaluation of chemical compound effects on gametocytes has continued to largely rely on microscopy-based assessment of Chevalley et al. [48] described a flow-cytometry-based method for the assessment of a compound's gametocytocidal activity. Gametocytogenesis was induced in sorbitol-synchronized P. falciparum W2 cultures by hematocrit drop, and gametocytes were isolated from asexual stages by the use of NAG and then further concentrated by magnetic separation. Stage IV-V gametocytes from 13 days old cultures were stained by hydroethidine and then quantified by flow cytometry. Gametocyte preparations were exposed for 48 hours to two reference compounds to validate the method for drug assay (table 4) . This method allows for the quantification (and potentially for testing drug sensitivity) of gametocytes of either sex independently, based on their different DNA content, and does not rely on transgenic parasite strains. However, the optimization studies required for the possible translation of this approach into a drug screening assay were not included in the report.
Additionally, issues of possible underestimation of parasite death by hydroethidine-based flow cytometric measurements have been recently raised [72] .
Throughout 2011, a series of reports on gametocytocidal assay development were published, utilizing several parasite strains, methods of gametocyte induction /purification and measurement approaches.
Peatey et al. [53] reported an assay methodology for late (IV to V) stage gametocytes based on an ATP bioluminescent readout. Transgenic 3D7 parasites carrying a Pfs16-GFP protein chimera gene [73] were synchronized and induced by exposure to spent medium, then young gametocytes were separated from asexual parasites using 50% and 35% percoll gradients, followed by further purification from uninfected erythrocytes by flow cytometry, thus exploiting the fluorescent properties of the chimeric protein. Stage I-II gametocytes, which were 99% pure, were cultured for 5-7 days to obtain stage IV-V gametocytes. These were then incubated with compounds in 96-wells plates for 24 hours, after which BacTiter-Glo was added to the cultures to allow for the measurement of the metabolic activity using a luminometer. The assay was validated by testing 6
known antimalarial compounds at a fixed concentration of 10µM and, later, with a panel of 44 current and experimental antimalarial compounds (table 4) [74] . The late stage gametocytes obtained by this method were synchronous, and the assay was described as sensitive, namely, that it can detect as low as 4000 gametocytes per well, with an excellent assay Z' value of 0.81.
On the other hand, to obtain the final assay biological material a quite elaborate manipulation of the parasite / gametocyte cultures was required, making it necessary to pool batches of previously purified, cryopreserved gametocytes to obtain the necessary volumes. Also, the incubation period with compounds was relatively short, being only 24 hours. Although it is desirable for the next generation antimalarial drugs to clear the parasites in a single dose [77] , therefore to be active in a short time frame, such a short incubation time in vitro does not simulate the situation of more common 3-day treatment courses, and may lead to slow-acting compounds being missed. Also, the gametocytemias obtained are rather low (approx.0.15% max), and no information is given on the dynamics of the GFP expression throughout gametocytogenesis, raising concerns about the possibility of spontaneous gametocytes also being detected together with the early stages. Finally, the use of flow cytometry for the assay readout appears difficult to readily translate into high throughput compatible assay, as described within the publication.
Tanaka & Williamson [50]
described an assay based on the measurement of general metabolic activity using an oxido-reduction indicator, Alamar Blue. Gametocytogenesis was stimulated in asynchronous 3D7 P. falciparum cultures by halving the hematocrit. NAG was added to the medium for 2 days, starting on day 9 from culture setup, to clear the culture from asexual parasites.
On day 12, gametocytes were purified using a 65% v/v Percoll density gradient and on day 13, stage III to V gametocytes were plated in 96-wells plates at 10-20% gametocytemia, and incubated for 72 hours with compounds. After a further 24 hours' incubation with Alamar Blue, the plates were centrifuged and the supernatant was transferred to fresh 96-well plates which were read using a fluorimeter. Six known antimalarial drugs were tested using this assay for validation purposes, (table 4) . One key strength of this assay is that it does not rely on a transgenic parasite strain, enabling this protocol to be used to screen the drug sensitivity of any 'wild type' parasite, even field isolates. The assay quality, is also among the highest of all of those identified in the literature, with a Z' factor of 0.81-0.87. The major drawbacks of this approach are the elaborate preparation steps before reading, including extra incubation and centrifugation / transfer steps, the high gametocytemia required per well and the lack of synchronicity of the gametocytes obtained , all potentially leading to reproducibility issues under HTS conditions. (Table 4) . Gametocyte inhibition was measured daily, allowing for the finest dissection of drug activity on synchronous gametocytes, both in terms of gametocyte stage and time required for inhibition. On the other hand, manipulation is demanding, because of the need for daily medium (containing drug) change during the incubation time and for plate centrifugation to concentrate the pellet before readout, and involves a freezing step. Also, no measurement is given of the assay quality, e.g. Z' value, as the assay was not performed in HTS format.
Lelièvre et al. [51]
recently published an assay based on ATP-bioluminescent reading for late stage gametocytes. Several parasite strains (3D7A, W2, NF54, Dd2 and fluorescent recombinant 3D7HT-GFP) were assessed for gametocyte production, leading to 3D7HT-GFP being selected. Cultures were induced through a 50% reduction in the hematocrit level. A combination of NAG and Bistratene A was then applied for 3-5 days to remove asexual stages from cultures. Stage IV-V gametocytes (1-2%) were then purified on day 15 after culture setup using a NicoPrep cushion and magnetic columns. This resulted in a final yield of 70% IV-V gametocytes. Gametocytes were seeded at 5 x 10 5 / 100 µl in 96-wells plates, then incubated for 48 hours with compounds.
BacTiter-Glo was added to the cultures before reading the output using a luminometer. A panel of 16 well known and described antimalarial compounds was assessed as part of the assay validation process (table 4) . Despite the choice of parasite strain selected for this study, in principal this method does not rely on recombinant parasites, therefore can be used with any parasite strain. Also, an excellent gametocyte synchronicity was achieved and the assay quality is sufficiently high (Z' = 0.68). This method, however, relies on the measurement of general cellular metabolic activity which is extremely sensitive to "contaminants", and thus requires elaborate purification steps to completely remove the uninfected erythrocytes.
Although all the methodologies reviewed here represent a substantial improvement over the manual gametocyte counting on Giemsa stained smears, they are all based on 96-well plates, and to the best of our knowledge, no adaptation to a truly HTS format (384-or 1536-wells format) has been reported to date.
There exist several other reports of assessment of P. falciparum gametocyte susceptibility to compounds [25, 70, 71, 73, [78] [79] [80] , however these have not been optimized for HTS or are not considered HTS compatible, thus they have not been discussed here. Table 4 provides a summary of the inhibitory activities reported for 24 reference compounds that
Gametocytocidal activity of compounds
were assessed during validation of the published gametocytocidal screening methodologies. Of these compounds, 13 were tested by at least two authors and allow for comparison of the inhibitory activity on gametocytes as determined using different HTS-amenable assay formats.
Chloroquine and mefloquine showed a similar inhibitory activity on early stage gametocytes and asexual stages [49] , in agreement with what is expected with quinoline derivatives. While chloroquine consistently lacked any activity on the later stage III to V gametocytes, irrespective of the method used [50, 51, 53, 74] , mefloquine resulted in a slightly higher and variable degree of inhibition at high concentrations. With this drug, 20% -50% inhibition at 10µM was observed in two independent assays [50, 74] whilst an IC 50 value of 4.7µM was attained in another [51] .
Quinine [50, 51] , lumefantrine and halofantrine [51, 54, 74] were similarly inactive on late stage gametocytes. The 8-aminoquinoline, primaquine, exhibited limited gametocytocidal activity.
Specifically, with stage I-II gametocytes no effect was observed by Buchholz et al [49] , whereas >75% inhibition was obtained by Adjalley et al [54] , at the high dose of 6.6µM, which is five times the IC 50 value for the asexual stages. Assays including stage III gametocytes reported a moderate 50 -75% inhibitory activity with primaquine concentrations of 6.6 -10µM [50, 54] . Stage IV and V gametocytes appear insensitive to the drug by all the screening methods used [51, 54, 74] . These findings contrast with the clinically demonstrated gametocytocidal properties of primaquine [20] .
However, the observed (lack of) inhibition in vitro may not truly reflect the situation in vivo, and the possible role played by the metabolic transformation of the parent compound into bioactive metabolites [81] . Tafenoquine, a closely related compound with important practical advantages over primaquine (specifically, longer half-life, less toxic, active on the sporogonic stages of malaria parasites), was tested in only one of the studies under review [54] , and showed comparable, moderate activity on early gametocytes as observed for asexual parasites, with minimal effect on the late sexual stages.
Late stage gametocytocidal activity associated with pyronaridine appears quite variable across the different assays and technologies used. No activity was found by Adjalley et al [54] , who tested it at a low maximal concentration of 85nM; pyronaridine was inactive at 10µM in the assay reported by Tanaka et al [50] , and yielded very different IC 50 values of 0.3 and 3.3µM in the assays of Peatey et al [74] and Lelievre et al [51] , respectively. Methylene blue, a promising thiazine dye with potent asexual stage inhibition activity, also yielded very different results in different assay settings. On committed schizonts and early stage I -II gametocytes a pro-inducing activity was observed by
Buchholz et al at sub-micromolar doses (0.125 and 0.031µM, respectively) [49] , a finding that should warrant further investigation as it suggests a possible gametocytogenesis stimulation and therefore potential risk of increased transmission of the disease should this drug be employed in large scale. At least 75% inhibition was observed with this drug, however, on stage I-II gametocytes at 15nM when assessed by an alternative assay [54] . Different late stage gametocyte assays also produced rather discrepant results for methylene blue with ≥50% inhibition being reported through a wide range of concentrations, 12 and 490nM [51, 54, 74] .
The hydroxy-naphthoquinone, atovaquone, was shown to have little inhibitory effect on stage I-II gametocytes in the early stage assay formats [49, 54] . The various methods testing stage IV and V gametocytes generally showed very little sensitivity to this drug, although with some contrasting results: no inhibition was reported by Peatey et al at 10µM [74] , an IC 50 value of 16.1µM was obtained by Lelievre et al [51] and some inhibition (20 -50%) was observed on stages V at the low concentration of 7.5nM by Adjalley et al [54] . Dihydroartemisinin showed very consistent results on early to mid-stage gametocytes, the most susceptible stages, with IC 50 values of 26nM, and above 75% inhibition at 12nM ( [49] and [54] , respectively). Although still sensitive to the drug, stage IV-V gametocytes were generally inhibited at higher doses, such as 90% at 10µM [50] and IC50 = 3.56µM [53] . Adjalley, however, observed inhibitions of 60% and 35% on stage IV and V, respectively, at a concentration of 0.12µM [54] . Artesunate, which was tested only against IV -V gametocyte in HTS assay format, showed a weak inhibition of these late gametocyte stages, with IC 50 values of 2.3µM [74] and 10.8µM [51] being reported. Unfortunately, the only two assays which tested the effects of pyrimethamine employed transgenic P. falciparum strains carrying a resistance to this drug [51, 74] .
With very few exceptions, the inhibitory activity of the reported reference compounds appears similarly high on asexual forms and on the early gametocytes stages (I-II), and shows a marked The recently reported assay methodologies offer hope for the identification of potent gametocytocidal compounds, representing a considerable advancement over the gold standard of microscopy-based counting. Several challenges, however, need to be addressed, including an agreed approach for the standardization and "quality control" of gametocyte cultures in term of stage synchronicity and yields. A broader translation of the new assay approaches to (at least) the 384-wells format is also necessary for a truly high-throughput screening capability to be reached, as well as an improved understanding of the potential benefits and drawbacks of the technologies used.
Once these challenges have been addressed, the hit compounds generated from screenings carried out in different laboratories employing different approaches could be readily cross validated for activity against early and late stage gametocytes before further in-depth investigation of their biological activity and progression through the drug development pipeline.
In an effort to address some of these issues, the Avery laboratory has optimized a method for the large scale induction and purification of P. falciparum gametocytes. Key issues identified and addressed to achieve a synchronous and high-yielding gametocyte culture included: i) standardizing the stress-based induction stimuli to maximize gametocyte conversion while minimizing the chances of parasite death due to excessive stress; ii) optimizing the gametocyte synchronicity through the appropriate timing of sorbitol-synchronization and magnetic purification steps.
Employing our method, gametocytemia levels obtained typically range between 1% and 4% on day 4, and the average gametocyte conversion rate is about 20% (unpublished data).
Two different assays for screening against early and late stage gametocytes, relying on luciferase activity measurement and high content imaging, respectively, were recently developed in our Extensive analysis will be required to determine whether any of the compounds identified through these studies have the potential to become the "anti-gametocyte" component of combination therapies. The most promising gametocytocidal hits emerging from the HTS campaigns will be further characterized for activity on the downstream development of the parasite (exflagellation, ookinete development) and, importantly, their transmission blocking activity will ultimately be validated in the rodent transmission model and/or in standard membrane feeding assays [82] . These necessary steps will likely reduce the number of viable compounds to progress, however, the amount of distinct chemical classes already identified bodes well for future malaria drug development.
Future perspective
As a consequence of the renewed support to malaria research aiming at eradication, the field of antimalarial drug discovery has never been more active, as testified by the recent large scale and open-access screening campaigns and by as many as 50 new series of small antimalarial molecules being patented within the last two years [83] . With the rapid increase of interesting chemical structures available for progression to antimalarial leads, it will be more and more important to prioritize the most promising ones in order to rationally commit the limited resources available for the expensive drug development process. A reliable, robust and cost effective high throughput assay directed against early and/or late stage P. falciparum gametocytes is one such tool enabling prioritization of vast numbers of chemical entities. respectively. Z' is a statistical parameter measuring the overall quality of a high throughput assay, by taking into account both the signal variability and the dynamic range (i.e. the gap between 0% and 100% inhibition samples) [74, 75] . The Z' parameter can be used to compare unrelated assays.
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